Status:
RECRUITING
Noninvasive Spinal Cord Stimulation for Early SCI
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
United States Department of Defense
Rivne Regional War Veterans Hospital, Spinal Cord Injury Rehabilitation Center
Conditions:
Spinal Cord Injuries
Bowel Dysfunction
Eligibility:
All Genders
19-65 years
Phase:
NA
Brief Summary
The investigators are looking to determine the safety and efficacy of non-invasive transcutaneous spinal cord stimulation (TSCS) in promoting recovery of lower urinary tract (LUT), bowel, sexual, and ...
Detailed Description
PURPOSE: The purpose of this clinical study is to investigate the safety and effectiveness of non-surgical transcutaneous spinal cord stimulation (TSCS) in helping with recovery of bladder function i...
Eligibility Criteria
Inclusion
- A participant must meet all of the following criteria in order to be eligible to participate:
- Age between 19 and 65 years at the time of consent
- Subacute SCI (time since injury 3-6months)
- ASIA Impairment Scale (AIS) A or B at spinal segments C5-T10
- Documented impaired LUT function
- Women of childbearing potential must not be intending to become pregnant, currently pregnant, or lactating. The following conditions apply:
- i. Women of childbearing potential must have a confirmed negative pregnancy test prior to the baseline visit.
- ii. Women of childbearing potential must agree to use adequate contraception during the period of the trial and for at least 28 days after completion of treatment. Effective contraception includes abstinence.
- Sexually active males with female partners of childbearing potential must agree to use effective contraception during the period of the trial and for at least 28 days after completion of treatment.
- Must provide informed consent.
- Agrees to comply with all planned visits and assessments, adhere with established bowel and LUT routines and refrain from initiation of new medications for bowel and LUT management without notifying the Principal Investigator of this study.
Exclusion
- A participant who meets any of the following criteria will be ineligible to participate:
- Clinically significant depression with thoughts of suicidal ideation (PHQ-9 total score above 20) or debilitating PTSD (PCL-5 total score above) or as judged by the investigator
- History of bladder augmentation or continent or incontinent urinary stoma or prior bladder surgery.
- Exhibits signs of lower motor neuron injury (i.e., concomitant conus medullaris/cauda equina injury).
- History of intradetrusor or intrasphincter onabotulinumtoxinA injections within 9 months of baseline visit.
- Concurrent use of any medication or treatment that in the opinion of the investigator interferes with study outcomes.
- Presence of cognitive impairments, social/psychological problems, or other comorbid conditions that, in the opinion of the Investigator, will preclude them from participation and completion of the study
- Presence of severe acute medical issues that interfere with testing (e.g., stage 3/4 pressure ulcers, uncontrolled diabetes).
- Contraindications for TSCS, such as:
- 1. Implanted Cardiac pacemaker 8.2 Implanted metal in the trunk or spinal cord 8.3 Intrathecal delivery system (e.g., baclofen pump) 8.4 Implanted central or peripheral neuromodulator
- Medical condition that may put the participant at risk as determined by the investigator.
- Participation in or plans to participate in another research study that may interfere with the study endpoints.
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06587841
Start Date
October 1 2024
End Date
October 1 2027
Last Update
November 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Blusson Spinal Cord Centre
Vancouver, British Columbia, Canada, V5Z 1M9